Bharat Immunological & Biological Corporation Ltd vs Divis Laboratories Ltd
A side-by-side comparison of Bharat Immunological & Biological Corporation Ltd (BIBCL) and Divis Laboratories Ltd (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divis Laboratories Ltd leads BIBCL vs DIVISLAB on 10 of 14 metrics (2 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Stock is trading at 0.92 times its book value"]
- − ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 5.09% over past five years.", "Company has a low return on equity of -22.7% over last 3 years.", "Debtor days have increased from 39.6 to 114 days."]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 11.5 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.